Screener
Discontinued — last reported Q4 '24
CapEx at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Spyre Therapeutics, Inc.’s 10-K, filed February 27, 2025.
- Filed
- Feb 27, 2025
- Fiscal year
- FY2024
- Accession
- 0001636282-25-000020
| Line item | Year Ended December 31, 2024 | Year Ended December 31, 2023 | Year Ended December 31, 2022 |
|---|---|---|---|
| CASH FLOWS FROM INVESTING ACTIVITIES | |||
| Cash assumed from asset acquisition of Spyre | — | 3,035 | — |
| Proceeds from sale of in-process research & development asset | — | 15,000 | — |
| Purchases of property and equipment | — | — | (38) |
| Proceeds from the sale of property plant and equipment | — | 475 | — |
| Purchases of marketable securities | (599,252) | (166,803) | (39,500) |
| Proceeds from maturities and sales of marketable securities | 245,967 | 39,900 | 96,546 |
| Net cash provided by (used in) investing activities | (353,285) | (108,393) | 57,008 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Spyre Therapeutics, Inc.'s capex?
- Spyre Therapeutics, Inc. (SYRE) reported capex of $0 in Q4 2024.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Spyre Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude